1:30pm Interview: Innovative Therapies: Development to the Patients with Emily Merrell, Director of Advanced Therapy Treatment Centres (ATTC) Network, Cell and Gene Therapy Catapult

 1:50pm Panel Discussion: From Trial to Treatment: Scaling Advanced Therapies

Translating Clinical Success into Real-World Treatment

• Key hurdles when moving from early clinical trials to late-stage development
• Aligning clinical endpoints with real-world patient outcomes
• Managing variability in response for cell and gene therapies

Manufacturing & Scalability Challenges

• Scaling manufacturing without compromising quality, safety, or efficacy
• Autologous vs allogeneic models: scalability trade-offs
• Technology innovations enabling cost reduction and consistency

Regulatory Pathways & Market Access

• Navigating evolving regulatory expectations across regions
• Accelerated approvals vs long-term evidence requirements
• Reimbursement challenges and demonstrating value to payers

Lessons Learned & Looking Ahead

• Biggest lessons from scaling therapies to date
• What companies should plan for earlier in development
• Future trends shaping the next generation of advanced therapies

Moderator: Emily Merrell, Director of Advanced Therapy Treatment Centres (ATTC) Network, Cell and Gene Therapy Catapult

Panellists:

Prasun Chakraborty, CEO, Genevation

Lindsay Davies, Chief Scientific Officer, NEXTCELL PHARMA AB

Diana Hernandez, Head of Translational Immunotherapy, Anthony Nolan Research Institute